Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review. Issue 4 (July 2020)

• Record Type: Journal Article
• Authors: Nakhleh, Afif; Shehadeh, Naim
• Is Part Of: Diabetes & metabolic syndrome. Volume 14:Issue 4(2020)
• Page Start: 509
• Page End: 512
• Publication Date: 2020-07
• Subjects: Diabetes mellitus -- COVID-19 -- ACE2 -- Glucose-lowering medications -- Insulin therapy; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2020.04.040
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background: Diabetes mellitus is associated with a more severe course of coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes angiotensin-converting enzyme II (ACE2) receptor for host cell entry. We aimed to assess the interactions between antihyperglycemic drugs and the renin-angiotensin system (RAS) and their putative roles in COVID-19. Methods: A literature search was performed using Pubmed to review the interrelationships between hyperglycemia, RAS and COVID-19, and the effects of antihyperglycemic medications. Results: The RAS has an essential role in glucose homeostasis and may have a role in COVID-19-induced lung injury. Some antihyperglycemic medications modulate RAS and might hypothetically alleviate the deleterious effect of angiotensin II on lung injury. Furthermore, most antihyperglycemic medications showed anti-inflammatory effects in animal models of lung injury. Conclusions: Some antihyperglycemic medications might have protective effects against COVID-19-induced lung injury. Early insulin therapy seems very promising in alleviating lung injury. Highlights: There seem to be considerable interrelationships between hyperglycemia and COVID-19. Renin-angiotensin system may have a putative role in COVID-19-induced lung injury. Some antihyperglycemic medications might have protective effects against COVID-19-induced lung injury.